科研工作 长期从事呼吸危重症和下呼吸道感染的临床和基础研究，2011年-2012年在Ho-Ho-Li奖学金资助下于美国斯坦福大学接受博士后培训。围绕重症感染进行了一系列研究，通过群体药代动力学研究建立了抗菌药物群体药代动力学模型，在老年重症感染患者中实现了美罗培南、万古霉素的个体化治疗，为抗菌药物合理化应用提供了有益数据。针对脓毒症的临床特征及发病机制进行了深入研究，建立了脓毒症队列，分析了基线指标和动态指标对于脓毒症预后的影响作用，建立脓毒症患者临床转归的早期预测模型。通过流式细胞检测、细胞因子和炎性介质分析、脂质代谢组学探讨脓毒症发生发展的机制，从而发现新的生物标志物和治疗靶点，对脓毒症的认识上开拓免疫与代谢这一交叉研究方向。此外也进行了呼吸衰竭、慢性阻塞性肺疾病、哮喘、胸部肿瘤等疾病相关研究。主持国家自然科学基金面上项目、北京大学第三医院队列建设项目、临床重点项目等科研项目。以第一作者或通讯作者在国内外主要期刊发表论文40余篇，其中SCI收录10余篇。 获奖情况 2023年荣获“北京大学优秀共产党员” 2022年荣获“北京大学第三医院2022年度优秀教师奖” 2020年荣获“敬佑生命 荣耀医者，专科精英奖-呼吸内科” 2020年荣获“北京大学优秀共产党员” 2018年荣获“北京大学优秀共产党员” 著作与译著 1. Li X*, Yin ZN*, Yan W, Wang M, Chang C, Guo CL, Xue LX, Zhou QT#, Sun YC#. Association between Changes in Plasma Metabolism and Clinical Outcomes of Sepsis. Emergency Medicine International 2023; 2023:2590115. 2. Yan W*, Sun XY*, Wang M, Zhao FF, Zhou QT#. Clinical Evaluation of a Vancomycin Dosage Strategy Based on a Serum Trough Concentration Model in Elderly Patients with Severe Pneumonia. Biomed Environ Sci 2023; 36(5):397-405. 3. Wang M*, Zhao F, Sun L, Liang Y, Yan W, Sun X, Zhou Q#, He B#. High-Flow Nasal Cannula versus Noninvasive Ventilation in AECOPD Patients with Respiratory Acidosis: A Retrospective Propensity Score-Matched Study. Can Respir J 2023; 2023:6377441. 4. Li X*, Yin Z*, Yan W, Wang M, Xue L, Zhou Q#, Sun Y#. Baseline red blood cell distribution width and perforin, dynamic levels of interleukin 6 and lactate are predictors of mortality in patients with sepsis. J Clin Lab Anal 2023; 37(3):e24838. 5. Zhang X*, Zhou Q*, Wang S, Ma Q, Sun Y#. Etiology of Emergency Visit and In-Hospital Outcomes of Patients with COPD. Emerg Med Int 2022; 2022:8247133. 6. Zhou Q*#, Zhao F, Wang M. An individualized administration model of vancomycin in elderly patients with sepsis and factors influencing augmented renal clearance. J Clin Pharm Ther 2021; 46(2):447-453. 7. Zhou Q*, Wang M, Li S, Zhang J, Ma Q, Ding Y, Ge H, Shen N, Zheng Y, Sun Y#. Impact of body mass index on survival of medical patients with sepsis: a prospective cohort study in a university hospital in China. BMJ Open 2018; 8(9):e021979. 8. Zhou QT*, He B#, Shen N, Liang Y, Sun LN. Meropenem Dosing Based on a Population Pharmacokinetic–Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract. Drugs Aging 2017; 34(2):115-121. 9. Zhou QT*, Mei JJ, He B#, Huang SG, Shi Y, Wen FQ, Zhao MW. Chronic obstructive pulmonary disease assessment test score correlated with dyspnea score in a large sample of Chinese patients. Chin Med J (Engl) 2013; 126(1):11-15. 10. Zhou QT*, He B#, Zhang C, Zhai SD, Liu ZY, Zhang J. Pharmacokinetics and Pharmacodynamics of Meropenem in Elderly Chinese with Lower Respiratory Tract Infections: Population Pharmacokinetics Analysis Using Nonlinear Mixed-Effects Modelling and Clinical Pharmacodynamics Study. Drugs Aging 2011; 28(11):903-912.